Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Zippelius

Showing results (31-40 of 35) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 35 results.
Swiss Medical Weekly|July 19, 2006
Clinical significance of cyclooxygenase-2 (COX-2) in multiple myelomaA Trojan, M Tinguely, S Vallet, et al.
ESMO Open|January 8, 2022
Targeting immunoliposomes to EGFR-positive glioblastomaB Kasenda, D König, M Manni, et al.
Cancer Science|March 1, 2008
MAGE-C1/CT-7 expression in plasma cell myeloma: sub-cellular localization impacts on clinical outcomeM Tinguely, B Jenni, A Knights, et al.
ESMO Open|April 10, 2022
Long-term outcomes of operable stage III NSCLC in the pre-immunotherapy era: results from a pooled analysis of the SAKK 16/96, SAKK 16/00, SAKK 16/01, and SAKK 16/08 trialsD König, S Schär, D Vuong, et al.
Immuno-Oncology Technology|January 13, 2025
Adoptive cell therapy with tumor-infiltrating lymphocytes in combination with nivolumab in patients with advanced melanomaD König, B Kasenda, M Sandholzer, et al.
Pageof 4

Showing results (31-40 of 35) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 35 results.
Swiss Medical Weekly|July 19, 2006
Clinical significance of cyclooxygenase-2 (COX-2) in multiple myelomaA Trojan, M Tinguely, S Vallet, et al.
ESMO Open|January 8, 2022
Targeting immunoliposomes to EGFR-positive glioblastomaB Kasenda, D König, M Manni, et al.
Cancer Science|March 1, 2008
MAGE-C1/CT-7 expression in plasma cell myeloma: sub-cellular localization impacts on clinical outcomeM Tinguely, B Jenni, A Knights, et al.
ESMO Open|April 10, 2022
Long-term outcomes of operable stage III NSCLC in the pre-immunotherapy era: results from a pooled analysis of the SAKK 16/96, SAKK 16/00, SAKK 16/01, and SAKK 16/08 trialsD König, S Schär, D Vuong, et al.
Immuno-Oncology Technology|January 13, 2025
Adoptive cell therapy with tumor-infiltrating lymphocytes in combination with nivolumab in patients with advanced melanomaD König, B Kasenda, M Sandholzer, et al.
Pageof 4